Queens University Belfast – Confidence in Concept 2019

Lead Research Organisation: Queen's University Belfast
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.

People

ORCID iD

Publications

10 25 50
publication icon
Bamford C (2021) Collaboration Between Host and Viral Factors Shape SARS-CoV-2 Evolution

publication icon
Broadbent L (2021) An Endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells

publication icon
Cornelius V (2021) Diabetic endotheliopathy: RNA-binding proteins as new therapeutic targets in The International Journal of Biochemistry & Cell Biology

publication icon
Cornelius VA (2021) Alternative Splicing: A Key Mediator of Diabetic Vasculopathy. in Genes

 
Description Opportunity-Led Professor Ultan Power - Repurposing FDA-approved drugs for treatment of 2019-nCoV-induced disease
Amount £208,070 (GBP)
Funding ID COM/5613/20 
Organisation Public Health Agency (PHA) 
Sector Public
Country United Kingdom
Start 10/2020 
End 09/2021
 
Description Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease.
Amount £640,433 (GBP)
Funding ID MRC - BMC DPFS - MR/W021641/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2022 
End 12/2024
 
Description Targeting Deubiquitinases to Treat Drug-Resistant Colorectal Cancer
Amount £225,656 (GBP)
Funding ID 56232 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 02/2021 
End 12/2023